<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05013099</url>
  </required_header>
  <id_info>
    <org_study_id>IAB-CD8-203</org_study_id>
    <nct_id>NCT05013099</nct_id>
  </id_info>
  <brief_title>Study of 89Zr-Df-crefmirlimab PET/CT in Subjects With Advanced or Metastatic Malignancies</brief_title>
  <official_title>A Phase IIB, Open Label, Study of 89Zr-Df-Crefmirlimab PET/CT in Subjects With Advanced or Metastatic Malignancies, Scheduled to Receive Immunotherapy (IOT) as a Single Agent or Combination, to Predict Response to Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImaginAb, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ImaginAb, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether 89Zr-Df-crefmirlimab PET can predict the&#xD;
      response of advanced or metastatic melanoma, Merkel cell carcinoma, renal cell carcinoma, or&#xD;
      non-small cell lung cancer tumors to immuno-oncology therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the performance of 89Zr Df crefmirlimab positron emission tomography/computed tomography (PET/CT) for predicting patient response to immunotherapy.</measure>
    <time_frame>Baseline to at least 24 or 27 weeks after the start IOT, depending on treatment schedule.</time_frame>
    <description>Best overall response (BOR) assessed by conventional imaging CT and/or MRI using RECIST 1.1 from 3 (or up to 3) consecutive imaging assessments (CT and/or MRI) following onset of immuno-oncology treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the performance of 89Zr Df crefmirlimab PET/CT for predicting lesion response to immunotherapy.</measure>
    <time_frame>Baseline to at least 24 or 27 weeks after the start IOT, depending on treatment schedule.</time_frame>
    <description>Largest measured difference from baseline in the lesion major axis from three (or up to three) consecutive standard of care imaging assessments (CT and/or MRI) following onset of immuno-oncology treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess safety of the repeat 89Zr Df crefmirlimab infusions.</measure>
    <time_frame>Up to 48 weeks or end of treatment.</time_frame>
    <description>Incidence and severity of AEs, infusion reactions, labs, and ECGs. Number of subjects withdrawn due AEs. Appearance of anti-drug antibodies.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluate 89Zr-Df-crefmirlimab PET/CT as a discriminator of pseudo-progression.</measure>
    <time_frame>Up to 48 weeks or end of treatment.</time_frame>
    <description>Incidence of iRECIST defined pseudo-progression events.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate 89Zr-Df-crefmirlimab PET/CT in subjects who develop clinical and/or radiographic progression to explore mechanisms for treatment resistance.</measure>
    <time_frame>Up to 48 weeks or end of treatment.</time_frame>
    <description>RECIST 1.1 defined Progressive Disease.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate 89Zr-Df-crefmirlimab PET/CT as a predictor or surrogate for IOT immune related adverse events (irAEs).</measure>
    <time_frame>Up to 48 weeks or end of treatment.</time_frame>
    <description>Incidence of Immuno-oncology related TEAEs in non-diseased tissues and organs.</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlate 89Zr-Df-crefmirlimab PET uptake with CD8 expression and PD 1/PD-L1 expression as determined by immunohistochemistry (IHC).</measure>
    <time_frame>Up to 48 weeks or end of treatment.</time_frame>
    <description>CD8 expressing cells and PD-1/PD-L1 expressing cells.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate 89Zr-Df-crefmirlimab PET/CT as a predictor of progression free survival (PFS)</measure>
    <time_frame>Up to 48 weeks or end of treatment.</time_frame>
    <description>Patient level Progression Free Survival.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate 89Zr-Df-crefmirlimab PET/CT as a predictor of duration of response (DoR).</measure>
    <time_frame>Up to 48 weeks or end of treatment.</time_frame>
    <description>Patient level Duration of Response.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Melanoma</condition>
  <condition>Merkel Cell Carcinoma, Unspecified</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Subjects with melanoma, Merkel cell, renal cell, or NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive up to three 89Zr-Df-crefmirlimab PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 3.0 mCi ± 20% and 4.5 mg API) as an IV infusion as follows: First scan within 14 days prior to the onset of IOT, and a second scan 4 to 6 weeks after start of immunotherapy. The second 89Zr-Df-crefmirlimab infusion and scan should be completed prior to the start of the third cycle of IOT. Subjects who are determined by the treating physician to have PD on immunotherapy can receive the optional third 89Zr-Df-crefmirlimab PET scan at the principal investigator's (PI's) discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>89Zr-Df-Crefmirlimab</intervention_name>
    <description>Up to three 89Zr-Df-crefmirlimab PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 3.0 mCi ± 20% and 4.5 mg API) as an IV infusion as follows: First (PETbaseline) within 14 days prior to the onset of IOT, and a second (PETEOC1) 4 to 6 weeks after start of immunotherapy. The second 89Zr-Df-crefmirlimab infusion and scan (PETEOC1) should be completed prior to the start of the third cycle of IOT. Subjects who are determined by the treating physician to have PD on immunotherapy can receive the optional third 89Zr-Df-crefmirlimab PET scan at the principal investigator's (PI's) discretion.</description>
    <arm_group_label>Subjects with melanoma, Merkel cell, renal cell, or NSCLC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects will be eligible for enrollment in the study if they meet ONE criteria a, b&#xD;
             or c in point 1 and ALL the criteria in points 2-9.&#xD;
&#xD;
               1. Subjects must meet ONE of the criteria a, b or c below:&#xD;
&#xD;
                    1. For enrollment into Cohort A: Subjects with histologically confirmed&#xD;
                       advanced or metastatic non-uveal/non-mucosal melanoma or merkel cell&#xD;
                       carcinoma (MCPyV positive and negative) who are not amenable to surgical&#xD;
                       cure and are candidates to receive single- or combined IOT alone (not to&#xD;
                       include cytotoxic chemotherapy) as first line treatment.&#xD;
&#xD;
                    2. For enrollment into Cohort B: Subjects with histologically confirmed&#xD;
                       advanced or metastatic nonpapillary Renal Cell Carcinoma who are not&#xD;
                       amenable to surgical cure and are candidates to receive single- or combined&#xD;
                       IOT alone or IOT in combination with tyrosine kinase inhibitor (not to&#xD;
                       include cytotoxic chemotherapy) as first or second line treatment.&#xD;
&#xD;
                    3. For enrollment into Cohort C: Subjects with histologically confirmed&#xD;
                       advanced or metastatic non-small cell lung cancer without non-smokers/driver&#xD;
                       mutations who are not amenable to surgical cure and are candidates to&#xD;
                       receive Atezolizumab as a monotherapy for first line treatment.&#xD;
&#xD;
                  Subjects must meet All of the criteria 2-9 below:&#xD;
&#xD;
               2. At least 1 RECIST 1.1-measurable. non-irradiated, non-cutaneous, non-osseous&#xD;
                  (unless there is an associated measurable soft-tissue component) lesion&#xD;
                  documented on intravenous (IV) contrast-enhanced CT or MRI (per RECIST criteria&#xD;
                  1.1) prior to first 89Zr-Df-crefmirlimab infusion.&#xD;
&#xD;
               3. Has an adequate washout period before the date of consent as defined by:&#xD;
&#xD;
               4. Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and anticipated&#xD;
                  survival of at least 6 months.&#xD;
&#xD;
               5. Subject must be IOT naïve.&#xD;
&#xD;
               6. Meeting all clinical safety lab values per institution's SOC, or investigator's&#xD;
                  discretion, for subjects receiving cancer treatment.&#xD;
&#xD;
               7. Male or female age ≥18 years.&#xD;
&#xD;
               8. Ability to understand the purposes and risks of the trial and has signed an&#xD;
                  Institutional Review Board (IRB) approved informed consent form.&#xD;
&#xD;
               9. Willingness and ability to comply with all protocol required procedures.&#xD;
&#xD;
              10. For men and women of child-producing potential, use of effective double barrier&#xD;
                  contraceptive methods during the study, up to 30 days after the last&#xD;
                  administration of the investigational product.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects will NOT be eligible for enrollment in the study if they meet ANY of the&#xD;
             following criteria:&#xD;
&#xD;
               1. Bone-only disease on conventional imaging (MRI, PET, CT) or skin- only lesions.&#xD;
&#xD;
               2. Serious nonmalignant disease or conditions that in the opinion of the&#xD;
                  investigator and/or ImaginAb could compromise protocol objectives.&#xD;
&#xD;
               3. Subjects with splenic dysfunction or who are status post splenectomy will be&#xD;
                  discussed on a case-by-case basis due to the importance of the spleen in CD8&#xD;
                  imaging as a reference tissue.&#xD;
&#xD;
               4. Pregnant women or nursing mothers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katherine Young</last_name>
    <phone>+1-310-645-1211</phone>
    <email>kyoung@imaginab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope (City of Hope National Medical Center, City of Hope Medical Center)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

